+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Urea Cycle Disorders Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Enzyme Deficiency Type, By Treatment Type, By Route of Administration, By Distribution Channel, By Company, and By Region

  • PDF Icon

    Report

  • 111 Pages
  • August 2023
  • Region: Global
  • TechSci Research
  • ID: 5852951
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global urea cycle disorders treatment market is anticipated to observe impressive growth during the forecast period 2023-2027. The major factors include the increasing prevalence of urea cycle disorder, and extensive research and development are driving the growth of the market globally. Urea cycle disorders (UCDs) are a group of genetic defects that constitute the urea cycle in the periportal liver cells. The other factors supporting the market's growth are rising investments in research and development activities by the government, increasing initiatives by key players, rising awareness among the masses, the presence of better healthcare services, and a growing number of innovative diagnostic approaches.

Rising Prevalence of urea cycle disorders among the Population

The growing prevalence of urea cycle disorders is likely to propel the growth of the market globally. According to reports published by the Centers for Disease Control and Prevention (CDC), the projected occurrence of urea cycle disorders is 1 in 8500 births. Owing to the many cases which remain undiagnosed and the newborns with the disorders die without a complete diagnosis; the exact numbers remain unknown. It is assumed that up to 20% of Sudden Infant Death Syndrome (SIDS) cases may be ascribed to an undiagnosed inborn error of metabolism, such as a urea cycle disorder which is anticipated to impel the urea cycle disorders treatment market.

Increasing Initiatives and Awareness Among Patients

Over the past few years, governments of different nations and private organizations have been taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments in research and development, increase in awareness programs, extensive research activities and clinical trials, and ease in approvals by the regulatory bodies are the supporting factors for the market. For instance, in 2017, Mead Johnson Nutrition Company (MJN) declared its merger with Reckitt Benckiser Group plc (RB). Mead Johnson, now a division of RB, included its globally recognized brands, incorporating Enfa and Nutramigen, which are used in the dietary management of urea cycle disorder, to RB's consumer health portfolio, thus bolstering its position globally. Similarly, in 2017, Horizon Pharma plc launched UCD in Common, an initiative for individuals suffering from urea cycle disorder, to offer educational, supportive, and interactive resources to the patients residing with UCD, their families, and healthcare specialists.

Market Segmentation

The global urea cycle disorders treatment market is segmented into enzyme deficiency type, treatment type, route of administration, distribution channel, and company. Based on enzyme deficiency type, the market is divided into carbamyl phosphate synthetase (CPS1), N-acetyl glutamate synthetase (NAGS), ornithine transcarbamylase (OTC deficiency), argininosuccinic acid synthetase (AS), argininosuccinate lyase (AL or ASA lyase), and arginase (AG). Based on treatment type, the market is divided into amino acid formulas, phenylbutyrate, sodium benzoate, and others. Based on the route of administration, the market is divided into oral and intravenous. Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. In terms of country, the United States is expected to be a lucrative market in the forecast period due to the rising number of cases of urea cycle diseases in the country.

Market Players

Bausch Health Companies Inc., Recordati Rare Diseases, Eurocept Pharmaceuticals Holding (Lucane Pharma SA), Acer Therapeutics, Ultragenyx Pharmaceutical, Aeglea BioTherapeutics, Arcturus Therapeutics, Inc., Orpharma Pty Ltd., Selecta Biosciences, Inc, and Abbott Laboratories, Inc. are some of the leading companies operating in the market.

Report Scope:

In this report, global urea cycle disorders treatment market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

Urea Cycle Disorders Treatment Market, By Enzyme Deficiency Type:

  • Carbamyl Phosphate Synthetase (CPS1)
  • N-Acetylglutamate Synthetase (NAGS)
  • Ornithine Transcarbamylase (OTC Deficiency)
  • Argininosuccinic Acid Synthetase (AS)
  • Argininosuccinate Lyase (AL or ASA Lyase)
  • Arginase (AG)

Urea Cycle Disorders Treatment Market, By Treatment Type:

  • Amino Acid Formulas
  • Phenylbutyrate
  • Sodium Benzoate
  • Others

Urea Cycle Disorders Treatment Market, By Route of Administration:

  • Oral
  • Intravenous

Urea Cycle Disorders Treatment Market, By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Urea Cycle Disorders Treatment Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • Europe & CIS
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in Urea Cycle Disorders Treatment Market

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview2. Research Methodology3. Impact of COVID-19 on Global Urea Cycle Disorders Treatment Market4. Voice of Customer5. Executive Summary
6. Global Urea Cycle Disorders Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Enzyme Deficiency Type (Carbamyl Phosphate Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS), Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG))
6.2.2. By Treatment Type (Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others)
6.2.3. By Route of Administration (Oral v/s Intravenous)
6.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
6.2.5. By Company (2021)
6.2.6. By Region
6.3. Market Map
7. North America Urea Cycle Disorders Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Enzyme Deficiency Type
7.2.2. By Treatment Type
7.2.3. By Route of Administration
7.2.4. By Distribution Channel
7.2.5. By Country
7.3. North America: Country Analysis
7.3.1. United States Urea Cycle Disorders Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Enzyme Deficiency Type
7.3.1.2.2. By Treatment Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By Distribution Channel
7.3.2. Mexico Urea Cycle Disorders Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Enzyme Deficiency Type
7.3.2.2.2. By Treatment Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By Distribution Channel
7.3.3. Canada Urea Cycle Disorders Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Enzyme Deficiency Type
7.3.3.2.2. By Treatment Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By Distribution Channel
8. Europe Urea Cycle Disorders Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Enzyme Deficiency Type
8.2.2. By Treatment Type
8.2.3. By Route of Administration
8.2.4. By Distribution Channel
8.2.5. By Country
8.3. Europe: Country Analysis
8.3.1. France Urea Cycle Disorders Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Enzyme Deficiency Type
8.3.1.2.2. By Treatment Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By Distribution Channel
8.3.2. Germany Urea Cycle Disorders Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Enzyme Deficiency Type
8.3.2.2.2. By Treatment Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By Distribution Channel
8.3.3. United Kingdom Urea Cycle Disorders Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Enzyme Deficiency Type
8.3.3.2.2. By Treatment Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By Distribution Channel
8.3.4. Italy Urea Cycle Disorders Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Enzyme Deficiency Type
8.3.4.2.2. By Treatment Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By Distribution Channel
8.3.5. Spain Urea Cycle Disorders Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Enzyme Deficiency Type
8.3.5.2.2. By Treatment Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By Distribution Channel
9. Asia-Pacific Urea Cycle Disorders Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Enzyme Deficiency Type
9.2.2. By Treatment Type
9.2.3. By Route of Administration
9.2.4. By Distribution Channel
9.2.5. By Country
9.3. Asia-Pacific: Country Analysis
9.3.1. China Urea Cycle Disorders Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Enzyme Deficiency Type
9.3.1.2.2. By Treatment Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By Distribution Channel
9.3.2. India Urea Cycle Disorders Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Enzyme Deficiency Type
9.3.2.2.2. By Treatment Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By Distribution Channel
9.3.3. Japan Urea Cycle Disorders Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Enzyme Deficiency Type
9.3.3.2.2. By Treatment Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By Distribution Channel
9.3.4. South Korea Urea Cycle Disorders Treatment Market Outlook
9.3.4.1. Market Size & Forecast
9.3.4.1.1. By Value
9.3.4.2. Market Share & Forecast
9.3.4.2.1. By Enzyme Deficiency Type
9.3.4.2.2. By Treatment Type
9.3.4.2.3. By Route of Administration
9.3.4.2.4. By Distribution Channel
9.3.5. Australia Urea Cycle Disorders Treatment Market Outlook
9.3.5.1. Market Size & Forecast
9.3.5.1.1. By Value
9.3.5.2. Market Share & Forecast
9.3.5.2.1. By Enzyme Deficiency Type
9.3.5.2.2. By Treatment Type
9.3.5.2.3. By Route of Administration
9.3.5.2.4. By Distribution Channel
10. South America Urea Cycle Disorders Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Enzyme Deficiency Type
10.2.2. By Treatment Type
10.2.3. By Route of Administration
10.2.4. By Distribution Channel
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Urea Cycle Disorders Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Enzyme Deficiency Type
10.3.1.2.2. By Treatment Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By Distribution Channel
10.3.2. Argentina Urea Cycle Disorders Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Enzyme Deficiency Type
10.3.2.2.2. By Treatment Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By Distribution Channel
10.3.3. Colombia Urea Cycle Disorders Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Enzyme Deficiency Type
10.3.3.2.2. By Treatment Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By Distribution Channel
11. Middle East and Africa Urea Cycle Disorders Treatment Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Enzyme Deficiency Type
11.2.2. By Treatment Type
11.2.3. By Route of Administration
11.2.4. By Distribution Channel
11.2.5. By Country
11.3. MEA: Country Analysis
11.3.1. South Africa Urea Cycle Disorders Treatment Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Enzyme Deficiency Type
11.3.1.2.2. By Treatment Type
11.3.1.2.3. By Route of Administration
11.3.1.2.4. By Distribution Channel
11.3.2. Saudi Arabia Urea Cycle Disorders Treatment Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Enzyme Deficiency Type
11.3.2.2.2. By Treatment Type
11.3.2.2.3. By Route of Administration
11.3.2.2.4. By Distribution Channel
11.3.3. UAE Urea Cycle Disorders Treatment Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Enzyme Deficiency Type
11.3.3.2.2. By Treatment Type
11.3.3.2.3. By Route of Administration
11.3.3.2.4. By Distribution Channel
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
14. Competitive Landscape
14.1. Bausch Health Companies Inc.
14.2. Recordati Rare Diseases
14.3. Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
14.4. Acer Therapeutics
14.5. Ultragenyx Pharmaceutical
14.6. Aeglea BioTherapeutics
14.7. Arcturus Therapeutics, Inc.
14.8. Orpharma Pty Ltd.
14.9. Selecta Biosciences, Inc
14.10. Abbott Laboratories, Inc.
15. Strategic Recommendations

Companies Mentioned

  • Bausch Health Companies Inc.
  • Recordati Rare Diseases
  • Eurocept Pharmaceuticals Holding (Lucane Pharma SA)
  • Acer Therapeutics
  • Ultragenyx Pharmaceutical
  • Aeglea BioTherapeutics
  • Arcturus Therapeutics, Inc.
  • Orpharma Pty Ltd.
  • Selecta Biosciences, Inc
  • Abbott Laboratories, Inc.

Related Topics

Related Reports

Urea Market by Grade, Form, Distribution Channel, Application - Global Forecast 2025-2030 - Product Image

Urea Market by Grade, Form, Distribution Channel, Application - Global Forecast 2025-2030

  • Report
  • 184 Pages
  • Global
From
U.S. - Urea - Market Analysis, Forecast, Size, Trends and Insights - Product Image

U.S. - Urea - Market Analysis, Forecast, Size, Trends and Insights

  • Report
  • United States
From
Middle East - Urea - Market Analysis, Forecast, Size, Trends and Insights - Product Image

Middle East - Urea - Market Analysis, Forecast, Size, Trends and Insights

  • Report
  • Middle East
From
Urea Cycle Disorders Treatment Global Market Report 2024 - Product Image

Urea Cycle Disorders Treatment Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Urea Cycle Disorders - Pipeline Insight, 2024 - Product Image

Urea Cycle Disorders - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.